As we usher in another brand-new year, I take this opportunity to share with you some important perspectives and developments in the industry and within our company which I feel will be drivers for our strategies and growth for the years ahead.

As you are aware, the Generic industry is facing numerous challenges and I foresee further consolidation in the times to come which in turn will cascade challenges to our CRO Industry as well. In light of this, we have already initiated measures to brace up to these challenges.

In 2019, we furthered our growth by a successful M&A which was one of the largest in the CRO space by acquiring a marquee asset -"Novum Pharmaceutical Research Services”, a specialized CRO in the Dermatology and Respiratory domains with strong technical strength of 300+ employees and facilities in Fargo, Las Vegas and Pittsburgh in the USA.

In parallel, am happy to announce that we have continued our impeccable regulatory track record of clearing various international regulatory inspections for our Clinical and Bioanalytical units. Our Mehsana Clinical Facility got accredited by ANVISA during the year 2019. It gives us the distinction of being one of the few CROs having multiple facilities being accredited by ANVISA to cater to our clients’ needs for the South American market.

On the Corporate Social Responsibility front, we have continued our initiatives by providing easy access to novel drugs in the field of life-threatening diseases for our less privileged members of the society. We continue our efforts towards blood donation camps and are associated with many NGOs for the growth and development of the society.

On the closing note, I would like to acknowledge my team, which continues to be committed with energy, positivity and integrity. They drive our values and work relentlessly to meet and exceed our client expectations.

Bindi Chudgar